Cargando…

Delivery of Active AKT1 to Human Cells

Protein kinase B (AKT1) is a serine/threonine kinase and central transducer of cell survival pathways. Typical approaches to study AKT1 biology in cells rely on growth factor or insulin stimulation that activates AKT1 via phosphorylation at two key regulatory sites (Thr308, Ser473), yet cell stimula...

Descripción completa

Detalles Bibliográficos
Autores principales: Siddika, Tarana, Balasuriya, Nileeka, Frederick, Mallory I., Rozik, Peter, Heinemann, Ilka U., O’Donoghue, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9738475/
https://www.ncbi.nlm.nih.gov/pubmed/36497091
http://dx.doi.org/10.3390/cells11233834
_version_ 1784847552604012544
author Siddika, Tarana
Balasuriya, Nileeka
Frederick, Mallory I.
Rozik, Peter
Heinemann, Ilka U.
O’Donoghue, Patrick
author_facet Siddika, Tarana
Balasuriya, Nileeka
Frederick, Mallory I.
Rozik, Peter
Heinemann, Ilka U.
O’Donoghue, Patrick
author_sort Siddika, Tarana
collection PubMed
description Protein kinase B (AKT1) is a serine/threonine kinase and central transducer of cell survival pathways. Typical approaches to study AKT1 biology in cells rely on growth factor or insulin stimulation that activates AKT1 via phosphorylation at two key regulatory sites (Thr308, Ser473), yet cell stimulation also activates many other kinases. To produce cells with specific AKT1 activity, we developed a novel system to deliver active AKT1 to human cells. We recently established a method to produce AKT1 phospho-variants from Escherichia coli with programmed phosphorylation. Here, we fused AKT1 with an N-terminal cell penetrating peptide tag derived from the human immunodeficiency virus trans-activator of transcription (TAT) protein. The TAT-tag did not alter AKT1 kinase activity and was necessary and sufficient to rapidly deliver AKT1 protein variants that persisted in human cells for 24 h without the need to use transfection reagents. TAT-pAKT1(T308) induced selective phosphorylation of the known AKT1 substrate GSK-3α, but not GSK-3β, and downstream stimulation of the AKT1 pathway as evidenced by phosphorylation of ribosomal protein S6 at Ser240/244. The data demonstrate efficient delivery of AKT1 with programmed phosphorylation to human cells, thus establishing a cell-based model system to investigate signaling that is dependent on AKT1 activity.
format Online
Article
Text
id pubmed-9738475
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97384752022-12-11 Delivery of Active AKT1 to Human Cells Siddika, Tarana Balasuriya, Nileeka Frederick, Mallory I. Rozik, Peter Heinemann, Ilka U. O’Donoghue, Patrick Cells Article Protein kinase B (AKT1) is a serine/threonine kinase and central transducer of cell survival pathways. Typical approaches to study AKT1 biology in cells rely on growth factor or insulin stimulation that activates AKT1 via phosphorylation at two key regulatory sites (Thr308, Ser473), yet cell stimulation also activates many other kinases. To produce cells with specific AKT1 activity, we developed a novel system to deliver active AKT1 to human cells. We recently established a method to produce AKT1 phospho-variants from Escherichia coli with programmed phosphorylation. Here, we fused AKT1 with an N-terminal cell penetrating peptide tag derived from the human immunodeficiency virus trans-activator of transcription (TAT) protein. The TAT-tag did not alter AKT1 kinase activity and was necessary and sufficient to rapidly deliver AKT1 protein variants that persisted in human cells for 24 h without the need to use transfection reagents. TAT-pAKT1(T308) induced selective phosphorylation of the known AKT1 substrate GSK-3α, but not GSK-3β, and downstream stimulation of the AKT1 pathway as evidenced by phosphorylation of ribosomal protein S6 at Ser240/244. The data demonstrate efficient delivery of AKT1 with programmed phosphorylation to human cells, thus establishing a cell-based model system to investigate signaling that is dependent on AKT1 activity. MDPI 2022-11-29 /pmc/articles/PMC9738475/ /pubmed/36497091 http://dx.doi.org/10.3390/cells11233834 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Siddika, Tarana
Balasuriya, Nileeka
Frederick, Mallory I.
Rozik, Peter
Heinemann, Ilka U.
O’Donoghue, Patrick
Delivery of Active AKT1 to Human Cells
title Delivery of Active AKT1 to Human Cells
title_full Delivery of Active AKT1 to Human Cells
title_fullStr Delivery of Active AKT1 to Human Cells
title_full_unstemmed Delivery of Active AKT1 to Human Cells
title_short Delivery of Active AKT1 to Human Cells
title_sort delivery of active akt1 to human cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9738475/
https://www.ncbi.nlm.nih.gov/pubmed/36497091
http://dx.doi.org/10.3390/cells11233834
work_keys_str_mv AT siddikatarana deliveryofactiveakt1tohumancells
AT balasuriyanileeka deliveryofactiveakt1tohumancells
AT frederickmalloryi deliveryofactiveakt1tohumancells
AT rozikpeter deliveryofactiveakt1tohumancells
AT heinemannilkau deliveryofactiveakt1tohumancells
AT odonoghuepatrick deliveryofactiveakt1tohumancells